Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4.
Much of the lung damage that limits the life of young adults with cystic fibrosis is due to proteases and oxygen metabolites generated by neutrophils, which are recruited into the airway by the interaction between Pseudomonas aeruginosa and pulmonary macrophages. Leukotriene B4 (LTB4) has been proposed as a local mediator of this process; its production is susceptible to specific modulation with dietary eicosapentaenoic acid (EPA). We carried out a placebo-controlled trial of EPA (2.7 g daily for 6 weeks) to assess its effects on markers of clinical state, peripheral neutrophil function, and lung inflammation in sixteen patients with cystic fibrosis colonised with P aeruginosa. EPA was well tolerated and resulted in a significant reduction in sputum volume (median change with EPA -10 mL/day, placebo 0; p = 0.015), and improvements in Schwachman score (EPA 5%, placebo 0; p = 0.034), forced expiratory volume in 1 s (EPA 0.25 L, placebo -0.1 L; p = 0.006), and vital capacity (EPA 0.6 L, placebo 0; p = 0.011). Relative chemotaxis of circulating neutrophils to LTB4 increased from a subnormal baseline of 4 (median; range 0-10) microns/30 min before treatment, to a near normal value of 11 (5-18) microns/30 min after EPA. Relative chemotaxis to LTB4 of patients taking placebo did not change: the difference in response was highly significant (p = 0.001). Specific reduction of neutrophil chemotaxis to LTB4 is a sensitive assay of chronic in-vivo exposure to LTB4. Our results suggest that LTB4 has a pathogenetic role in the lung damage of cystic fibrosis. Longer-term clinical trials of EPA are warranted in a larger number of cystic fibrosis patients.
Lawrence
R
R
Centre for Infectious Diseases and Microbiology, University of Sydney, Westmead Hospital, New South Wales, Australia.
Sorrell
T
T
D000293:Adolescent; D000328:Adult; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism / Q000382:microbiology; D004041:Dietary Fats / Q000008:administration & dosage; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007958:Leukocyte Count; D007975:Leukotriene B4 / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D010865:Pilot Projects; D010919:Placebos; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D013183:Sputum / Q000737:chemistry / Q000166:cytology / Q000382:microbiology; D014797:Vital Capacity / Q000187:drug effects / Q000502:physiology
D004041:Dietary Fats; D010919:Placebos; D007975:Leukotriene B4; D015118:Eicosapentaenoic Acid